Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Capricor Therapeutics Q1 2024 GAAP EPS $(0.31) Misses $(0.11) Estimate, Sales $4.906M Miss $9.700M Estimate

Author: Benzinga Newsdesk | May 13, 2024 04:16pm

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.11) by 181.82 percent. This is unchanged from the same period last year. The company reported quarterly sales of $4.906 million which missed the analyst consensus estimate of $9.700 million by 49.42 percent. This is a 64.25 percent increase over sales of $2.987 million the same period last year.

Posted In: CAPR